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Abstract
Background: Enzyme replacement therapy (ERT) with laronidase, (recombinant human α-L-iduronidase; Aldurazyme)
is the primary treatment option for patients with attenuated mucopolysaccharidosis type I (MPS I). This study examined
the effect of early ERT on clinical manifestations.
Methods: This multinational, retrospective case series abstracted data from records of 20 patients with Hurler-Scheie
syndrome within nine sibships that included older siblings treated with laronidase after the development of significant
clinical symptoms, and younger siblings treated before significant symptomatology. Median age at diagnosis was 5.6
and 0.5 years for older and younger siblings, respectively. Median age at ERT initiation was 7.9 and 1.9 years for older
and younger siblings, respectively.
Results: Improvement or stabilization of somatic signs and symptoms was more notable in younger siblings.
Organomegaly present at onset of ERT improved in the majority of both older and younger siblings. Analysis of
physician-rated symptom severity demonstrated that cardiac, musculoskeletal, and cognitive symptoms, when
absent or mild in younger siblings at ERT initiation, generally did not develop or progress. The majority of older
siblings had height/length Z-scores greater than two standard deviations below the mean (less than -2) at both
time points. In general, Z-scores for younger siblings were closer to the sex- and age-matched means at follow-up.
Conclusions: These findings suggest early initiation of laronidase, prior to the onset of symptoms in patients with
attenuated MPS I, can slow or prevent the development of severe clinical manifestations.
Keywords: Enzyme replacement therapy, Early diagnosis, Early treatment
Background
Mucopolysaccharidosis type I (MPS I) is an autosomal
recessive disorder caused by deficient α-L-iduronidase
activity, a lysosomal enzyme involved in degradation of
the glycosaminoglycans (GAGs) heparan and dermatan
sulfate. Enzyme deficiency leads to accumulation of
GAGs in multiple tissues resulting in a progressive and
multisystem disease. MPS I includes a spectrum of clinical
presentations ranging from severe (Hurler syndrome) to
attenuated (Hurler-Scheie, [H/S] and Scheie syndromes)
[1]. Patients with Hurler syndrome develop coarse facial
features, debilitating skeletal disease, organomegaly, cogni-
tive impairment, and cardiac and respiratory disease
shortly after birth. Patients with H/S have mild or no cog-
nitive impairment; however somatic symptoms result in
significant disease morbidity and reduce life expectancy to
the second or third decade of life. Disease progression is
slowest in patients affected with Scheie syndrome.
Treatment options include hematopoietic stem cell
transplant (HSCT) recommended before 2.5 years of age
for patients with the most severe phenotype, and enzyme
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replacement therapy (ERT) with laronidase (recombinant
human α-L-iduronidase; Aldurazyme®) indicated as the
primary treatment option for patients with attenuated
MPS I [2]. Laronidase administration is safe and effective,
and improvements in clinical manifestations and
stabilization of disease progression are achieved in pa-
tients with varying degrees of disease severity [3–6]. The
long-term clinical benefits achieved with ERT appear to be
largely dependent on early diagnosis and treatment [7].
Clinical features such as cardiac valve disease, corneal
clouding, and skeletal changes do not respond as well to
ERT since irreversible pathology may be established by the
time symptoms appear [8].
Due to the large phenotypic heterogeneity seen in MPS
I, correlating ERT timing to the effect on the clinical
course and progression of symptoms can be challenging.
However, it is evident from assessing treatment outcomes
in siblings with similar genetic backgrounds and expected
rates of disease progression that pre-symptomatic initi-
ation of ERT drastically alters the clinical course of MPS I
[9, 10]. In two sets of siblings, more serious clinical find-
ings were well documented for older siblings initiating
ERT later in life after the onset of symptoms compared
with their younger counterparts who commenced treat-
ment before disease manifestations were apparent. In both
cases, early ERT prevented the development of many clin-
ical features of MPS I in the younger sibling [9, 10].
Here, we present the largest compilation of sibling
data to date for patients with the H/S phenotype. This
case series examines data from sibling pairs/sibships that
included older siblings treated with laronidase after the
development of significant clinical symptoms, and youn-
ger siblings, the majority of whom initiated laronidase
before significant symptomatology.
Methods
This multinational, retrospective, chart review case
series was conducted at the authors’ institutions. All pa-
tients with MPS I diagnosed by enzyme biochemical de-
termination and/or molecular analysis were treated with
laronidase according to prescribing information (weekly
intravenous infusions of 100 U/kg of body weight).
Sibships were identified where younger siblings initiated
ERT at an earlier age than older siblings. In general,
older siblings initiated treatment with laronidase after
the onset of MPS I symptoms while younger siblings ini-
tiated ERT before onset of significant physical and clin-
ical symptoms. Written informed consent was provided
by the legal guardians/parents of all patients.
Treating physicians completed questionnaires asses-
sing signs and symptoms of MPS I prior to and follow-
ing ERT. Data from patient records, medical histories
and neurological, cardiovascular, pulmonary, gastro-
enterology, musculoskeletal, ophthalmologic, audiologic,
and psychomotor developmental examinations were
abstracted including:
Height/length (absolute); Description of facial features
observed during physical examination; Presence of corneal
opacity, hearing loss/use of hearing aids, sleep apnea, her-
nia; Results of pulmonary function tests (PFT); Liver and
spleen size determined by palpation and/or imaging stud-
ies; Cardiac disease description/severity determined from
echocardiogram; Joint and skeletal disease observed during
physical examination and/or radiographic imaging; Pres-
ence/severity of dysostosis multiplex, joint contractures
and affected joints; Motor development assessed during
physical examination; Cognitive and language development
assessed by formal evaluation or by investigator impres-
sion; and Ability to perform activities of daily living (ADL).
Data were abstracted at a time point just prior to initi-
ating ERT (Time point 1, T1) and follow-up data were
collected after at least 3 years of ERT (Time point 2, T2).
Data analysis
The frequency of signs and symptoms at T1 was deter-
mined from a maximum value of 14 symptoms that in-
cluded coarse facial features, corneal clouding, hearing
loss, sleep apnea, abnormal PFT, cardiac abnormalities,
hepatomegaly, splenomegaly, hernia, dysostosis multi-
plex, joint contractures, motor developmental delay, lan-
guage/cognitive delay, and restrictions in ADL.
Symptom severity was rated by physicians for corneal
opacity, cardiac symptoms, dysostosis multiplex, and
joint contractures. Z-scores for height/length were cal-
culated according to National Health and Nutrition
Examination Survey and Center for Disease Control
Growth Chart Information as revised on June 8, 2000.
Results
Twenty patients within nine sibships (seven sibling pairs
and two sets of three siblings) were identified from nine
centers in Argentina (two sites), Brazil, France, Spain,
Saudi Arabia, UK, and the US (two sites). Median age
(range) at diagnosis was 5.6 years (1, 9) for older siblings
(n = 10) and 0.5 years (0, 6.7) for younger siblings (n = 10).
All older siblings initiated laronidase by 14 years of age,
while younger siblings initiated therapy before 4 years
of age (with one exception). Five younger siblings (sib-
ships 1–5a) were diagnosed at less than 1 year of age
and initiated treatment by 1.3 years of age. For analysis
of responses to treatment, these patients are presented
together as Group A. A second group of younger siblings
(Group B, sibships 5b–8) began laronidase treatment after
age 2. Age at diagnosis, treatment, and duration of treat-
ment for each patient, and median data by group are pre-
sented in Table 1. Older and younger siblings within a
sibship had similar ERT duration.
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Figure 1 summarizes the percentages of signs and
symptoms present at T1 (out of the total number of
signs/symptoms assessed per patient) for all patients
by sibship. Younger siblings (blue bars) generally had
fewer symptoms than older siblings (red bars) at T1,
particularly in Group A. All older siblings were symp-
tomatic at T1.
Treatment outcomes
Symptom severity as rated by physicians for key clinical
symptoms at T1 and T2 is coded by color in Fig. 2.
Symptoms were absent or mild for younger siblings in
Group A. For younger siblings in Group B, symptom fre-
quency was greater, but motor and cognitive develop-
mental deficits were typically less severe than for older
Table 1 Demographics and baseline characteristics of individual patients
Sibship ID Pt ID Sex Genotype Age at diagnosis (yr) Age at ERT Initiation (T1) (yr) Duration of ERT at T2 (yr)
Group Aa
1 OS F P533R/P533R 8 8.8 5.4
1 YS M P533R/P533R 0.2 0.3 4.5
2 OS M P533R/P533R 1.3 3.3 11.7
2 YS F P533R/P533R Birth 0.4 9.6
3 OS F NA 1 12 8
3 YS F NA 0.4 0.7 8.3
4 OS M G208D/P520R 3.6 5.5 3.5
4 YS M G208D/P520R 0.8 1.3 3.6
5a OS F L490P/L490P 3 5.8 8.6
5a YS1 M L490P/L490P 0.1 0.3 7.6
Group A Median (range)
OS YS OS YS OS YS
N = 5c N = 5 N = 5c N = 5 N = 5c N = 5
3.0 0.2 5.8 0.4 8.0 7.6
(1, 8) (0, 0.8) (3.3, 12) (0.3, 1.3) (3.5, 11.7) (3.6, 9.6)
Group Bb
5bc OS F L490P/L490P 3 5.8 8.6
5b YS2 F L490P/L490P 0.1 2.5 8.8
6 OS1 M NA 9 13 6
6 OS2 M NA 8 11 6
6 YS M NA 0.6 3 7
7 OS F P533R/L564fsx 4.3 4.5 5.5
7 YS F P533R/L564fsx 3.3 3.4 5.6
8 OS M NA 6.8 7 6.0
8 YS M NA 3.3 3.7 5.8
9 OS F NA 7 14 7
9 YS F NA 6.7 8.6 6.4
Group B Median (range)
OS YS OS YS OS YS
N = 6 N = 5 N = 6 N = 5 N = 6 N = 5
6.9 3.3 9.0 3.4 6.0 6.4
(3, 9) (0.1, 6.7) (4.5, 14) (2.5, 8.6) (5.5, 8.6) (5.6, 8.8)
F female, M male, NA not available, OS older sibling, YS younger sibling
aGroup A: younger siblings ERT onset ≤1 year of age
bGroup B: younger siblings ERT onset between 2 and 4 years (except #9 at 8.6 year)
cThe older sibling in sibship 5 is listed twice (once in group A and once in Group B) since one of the two younger siblings initiated ERT at 0.3 years of age
(sibling 2a, Group A) and the other at 2.5 years of age (sibling 2b, Group B), respectively
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siblings. All patients had improvement or stabilization of
some somatic signs and symptoms at the T2 assessment.
In general, organomegaly present at ERT onset improved
in both older and younger siblings. Earlier treatment
with laronidase did not prevent development of corneal
clouding in patients asymptomatic at time of treatment.
However, analysis of cardiac, musculoskeletal, and motor
and cognitive development indicate that younger siblings
were less likely to develop or have progression of some
symptoms compared to the older siblings in the sibships.
For younger siblings in Group A, who had fewer and
more mild symptoms at T1, cardiac and musculoskeletal
symptoms generally remained mild or had not developed
at the T2 assessment. This was particularly apparent in
sibships 1, 3, 4, and 5. For younger siblings in Group B,
who had a higher incidence of moderate or severe symp-
toms at T1, cardiac or musculoskeletal symptoms gener-
ally were not as severe and did not progress compared to
older siblings.
Sibship 1
The younger patient had no major somatic signs or
symptoms prior to initiating laronidase and had normal
psychomotor development. At T2, after almost 5 years
of ERT, there was no development of cardiac or muscu-
loskeletal disease, and except for stabilization of upper
airway obstruction and development of mild hernia, the
child remains in good health. In contrast, the older
sibling already had significant symptoms at 8 years of
age (T1). In addition to symptoms noted in Fig. 2, the
patient had mild hearing loss and psychomotor delay,
speech difficulty, and lung function tests 50 % of normal.
The patient required help in all ADL. Symptoms present
at T1 were stabilized or improved (organomegaly and
hearing) at T2, except for worsening of kyphoscoliosis.
Sibship 2
The younger sibling was 5 months of age at T1 and
already had cardiac symptoms ranging from mild to severe
(Fig. 2), and mild organomegaly. After 10 years of ERT,
cardiac symptoms showed some improvement into the
mild to moderate range, and organomegaly stabilized. De-
velopment remained normal. The older sibling had mild
organomegaly and cardiac involvement by age 3 at T1,
which remained mild with therapy. Motor development
remained normal while learning difficulties present at on-
set of ERT persisted. Both siblings had progression of
musculoskeletal symptoms, although severity remained
milder in the younger sibling. Spinal radiographic find-
ings for sibship 2 are shown in Fig. 3. Panels A and B
are radiographs of the older sibling at age 8, after
5 years of ERT, showing significant scoliosis and other
spinal deformities. Panels C and D are spinal radio-
graphs of the younger sibling at age 10, after 10 years
of ERT, showing the absence of spinal deformity.
Fig. 1 Symptoms present at T1 for Older (OS) and Younger (YS) Siblings. Frequency of signs and symptoms at T1 was determined from a maximum
of 14 possible symptoms that included coarse facial features, corneal clouding, hearing loss, sleep apnea, abnormal lung function tests,
cardiac abnormalities, hepatomegaly, splenomegaly, hernia, dysostosis multiplex, joint contractures/other skeletal defects, motor developmental delay,
language/cognitive delay, and restrictions in ADL
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Sibship 3
The older sibling had significant limitations in ADL, mod-
erate musculoskeletal disease, and moderate to severe
cognitive delay and delays in fine and gross motor devel-
opment when ERT was initiated at 12 years of age. All
existing symptoms persisted or progressed in this sibling
except for improvement in organomegaly. The younger
sibling began ERT at 8 months of age and after 8 years had
no restrictions in ADL, no cognitive delays, and only mild
musculoskeletal symptoms and mild to moderate ocular
disease. Cardiac symptoms remained stable.
Sibship 4
Siblings had normal fine and gross motor development
and were able to walk unassisted prior to the start of
ERT. The older sibling also had no cardiac symptoms at
T1. Cardiac disease was mild in both siblings at T2;
other symptoms stabilized, except for progression of
respiratory symptoms. Cognitive delays persisted in the
older sibling, and developed in the younger. Both siblings
had poor compliance (~60 %) with ERT, which may have
impacted the symptom progression.
Sibship 5 (three siblings)
Two siblings initiated ERT before 5 years of age, one prior
to the development of any symptoms, and one after mild
cardiac symptoms, ocular disease, and organomegaly, and
moderate delays in motor skills were apparent. Similar
symptoms (except for the presence of moderate to severe
organomegaly) were present in the oldest sibling who
began ERTat 5.8 years of age. Additionally, this sibling pre-
sented with mild joint contractures at this time. At T2,
there were improvements in organomegaly and motor
function. Pulmonary function was at 30–40 % of normal at
follow-up (no information available at T1). Ocular involve-
ment and lower extremity joint symptoms progressed, but
cardiac disease remained stable. In the sibling who initiated
Fig. 2 Physician-rated Severity of Symptoms at T1 and T2. Figure 2 Severity of Symptoms at T1 and T2. Severity of key clinical symptoms for older
and younger siblings in at the initiation of ERT (T1) and at follow-up (T2) was rated by physicians. Results are organized by group and coded by
color. Symptoms were absent, or ranged in severity from mild to severe
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ERT at 2.5 years, organomegaly and motor function delays
improved, cardiac symptoms remained stable, and mild
joint contractures developed. The sibling who began
ERT at <1 year of age remained healthy, with the ex-
ception of mild ocular and cardiac symptoms. Psycho-
motor development remained normal and there were no
limitations in ADL. In both younger siblings, pulmonary
function was between 70 and 94 % of normal at T2. In
general, the severity of symptoms in the youngest sibling
remained milder than those of the other siblings.
Sibship 6 (three siblings)
Two siblings initiated ERT at 11 and 13 years, respect-
ively, and the youngest began ERT at 3 years of age. All
three siblings had mild cardiac and musculoskeletal
symptoms at T1. Cardiac symptoms remained mild at
T2, and joint contractures progressed in all three sib-
lings and were severe at T2. However, dysostosis multi-
plex progressed only in the older siblings to moderate to
severe, and remained mild in the younger sibling. Pul-
monary function was 45–50 % of normal in the two
older siblings at T2, and 70–80 % of normal in the youn-
ger sibling. None of the siblings had restrictions in ADL.
Sibship 7
Both siblings began ERT prior to 5 years of age and had
significant somatic, motor, and cognitive impairments
prior to initiating therapy. After 5 years of ERT, cardiac
symptoms stabilized, and musculoskeletal symptoms and
motor development improved in the older sibling. Cardiac
symptoms progressed in the younger sibling but remained
mild. Corneal clouding progressed in both siblings. In the
younger sibling who began both intensive physiotherapy
and speech therapy at the age of 5, motor development
remained normal, and cognitive skills and musculoskeletal
disease improved.
Sibship 8
Both siblings had progression of cardiac symptoms at
T2. Dysostosis multiplex stabilized in both siblings, and
remained milder in the younger sibling. The younger
sibling’s joint contractures progressed into the moderate
range. While the older sibling had behavioral issues and
required an aide for 1-on-1 schooling, the younger sibling
had no such issues.
Sibship 9
Both siblings began ERT at a late age (14 and 8.6 years
of age, respectively), and had similar symptom profiles at
T1, with ocular, respiratory, cardiac, and musculoskeletal
involvement. At T2, ocular and cardiac symptoms pro-
gressed from mild to moderate/severe in the older
sibling. In addition, pulmonary function worsened, and
contractures and lower extremity weakness progressed.
In contrast, the younger sibling had stabilization of mild
ocular symptoms, and cardiac disease remained less
severe in the mild to moderate range. Both patients had
stabilization of dysostosis multiplex and no progression
of motor function delays.
Fig. 3 Spinal radiographs from sibship 2 patients. Panel a and b show
radiographs of the older sibling at age 8, after 5 years of ERT. Note the
‘S’ shaped scoliosis with right-sided convexity in the thoracic region and
left-sided convexity in the lumbar region as well as gibbus deformity at
L1 and L4. There is retrolisthesis of L4 with respect to L5 and possible
compromise in the spinal canal at L1 and L4. Small anterior beaking is
noted in the lower thoracic and lumbar vertebrae. Panel c and d are
spinal radiographs of the younger sibling at age 10, after 10 years of
ERT. Note the absence of spinal deformity with only minimal anterior
beaking of the lower thoracolumbar vertebrae
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All older siblings except those from sibships 2 and
8 had Z-scores greater than two standard deviations
below the mean (less than −2). At T2, Z-scores devi-
ated further from the mean in the majority of the
older siblings. Although remaining two standard devi-
ations below the mean, in sibship 4, the Z-score im-
proved from −3 to −2 and in sibship 9 improved
from −6 to −5.6. In general, Z-scores for younger sib-
lings at T2 were closer to sex- and age-matched
means. For 6/9 of the younger siblings, Z-scores
ranged from +0.88 to −1.4 at T2, and represented ei-
ther improvements in height/length or no significant
change from T1. For the younger siblings in sibships
6 and 9, the Z-scores at T2 were more negative than
at T1 with height/length 2.5 or more standard devia-
tions from the mean. Importantly, in all sibships (with
the exception of sibship 6) the heights of the younger
siblings at T2 were greater than their older siblings at
comparable ages. Height/length Z-scores for all sib-
ships at T1 and T2 are shown in Fig. 4.
Discussion
The data collected from this multinational case series
demonstrate the benefit of early ERT initiation in pa-
tients with attenuated MPS I. Laronidase is believed to
stabilize but not improve cardiac and skeletal/connective
tissue disease when pathological changes are already
present at the start of treatment, and early ERT may
help prevent the onset of disease features [8]. However,
there are limited studies in young patients with clinically
significant somatic symptoms prior to initiation of ERT.
The pivotal laronidase clinical trial for MPS I enrolled
patients 5 years of age and older [6]. A subsequent trial
enrolled patients younger than 5 years of age and re-
ported improved clinical status after 1 year of treatment
with no safety concerns [5]. Previously-published single
case studies in siblings with MPS I support the pre-
symptomatic initiation of ERT to prevent or delay many
clinical manifestations of the disease [9, 10]. The alteration
of clinical disease progression has also been described in
sibling pairs with MPS VI where early, pre-symptomatic
Fig. 4 Z-scores for height/length at T1 (time of ERT initiation) and T2 (follow-up) for older (OS) and younger siblings (YS). Group A: younger siblings
ERT onset ≤1 yr of age (sibships 1-5a; Group B: younger siblings ERT onset between 2 and 4 yrs (except sibship 9 at 8.5 yr) (sibships 5b through 9)
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initiation of ERT in the younger sibling resulted in preven-
tion of symptoms, including bone deformities, and sus-
tained benefits over 10 years of treatment [11–13]. Studies
in animal models of MPS I also support early initiation of
ERT. Laronidase treatment initiated soon after birth in
affected dogs and mice improves outcomes and prevents
cardiac and skeletal disease [14, 15]. Our comparison of
disease progression following laronidase treatment in a
series of older and younger siblings with MPS I lends
additional support to the value of early ERT initiation.
Grouping sibships based on the age of ERT initiation in
the younger sibling provided additional insight into the
benefits of early treatment and the development of clinical
features. In Group A (younger sibling initiated treatment
≤1.3 years of age), mild to severe symptoms were noted
before treatment initiation in older siblings while symp-
toms were absent to mild in younger siblings. Most strik-
ing is the continued absence of clinical symptoms in the
younger sibling from sibship 1 after nearly 5 years of ERT
contrasted to the stabilization, but not reversal, of symp-
toms in the older sibling. Prominent differences were seen
within other sibships in Group A for corneal opacity,
organomegaly, dysostosis multiplex, and joint contrac-
tures. The extent of cardiac involvement was variable
amongst siblings; however, improvement or stabilization
of symptoms was noted following ERT. Younger siblings
in Group A also tended to have fewer delays in motor and
cognitive function, and less restriction in ADL.
For Group B (younger sibling initiated treatment
between 2 and 4 years, with the exception of sibship 9),
symptoms present in older siblings at T1 ranged from mild
to severe. In younger siblings, symptoms generally ranged
from absent to moderate, largely depending on the age
treatment was initiated. At T2, symptoms noted in younger
siblings at the time of ERT initiation either improved or
stabilized, and only one developed symptoms classified as
severe (sibship 6; joint contractures). Clinical differences
were noted between older and younger siblings in Group B
for organomegaly and dysostosis multiplex. Following
treatment initiation, older siblings experienced improve-
ments (especially in symptoms that were severe at baseline)
or stabilization while younger siblings in this group experi-
enced slower and less severe disease progression.
Short stature is a key clinical feature of MPS I. The
rate of growth in children with MPS I is slower than in
the healthy population, and differences in height be-
tween healthy and affected children increase with age
[16]. Some studies have not found early ERT therapy to
be associated with improved growth patterns in children
with attenuated MPS I [16, 17]. However, a case study of
three siblings reported stabilized or improved growth in
two of three siblings who initiated laronidase therapy be-
fore 5 years of age [10]. In contrast, growth was further
from the normal population mean in the third sibling
who initiated laronidase therapy at age 6. Our data sup-
port the findings that ERT does not lead to improve-
ment in growth. However, younger siblings remained
taller than their older counterparts at a comparable age.
As a retrospective study, our analyses were limited by
lack of control over the primary data collection, missing
data, and issues with objective data analysis. While we
recognize that the assessment of symptoms severity by
physicians was subjective and could be influenced by
sociocultural differences in medical practice, it is import-
ant to note that the patients were followed for most of
their lives by the same physicians, who were able to com-
pare symptoms in the siblings for a number of years and
through various developmental stages. We believe this fac-
tor can limit the bias in assessing severity between sib-
lings. Given the difficulties in conducting randomized
controlled trials in the setting of a rare disease, and the
geographical dispersion of patients with MPS I, we believe
that comparing data between the siblings rather than
across patients is an effective retrospective design. While
comparing siblings is an insightful model to better under-
stand the benefits of early treatment initiation in MPS I
due to similar genetic backgrounds, there are a number of
factors to consider. Phenotypic variability resulting from
the effects of modifying polymorphisms is known to occur
with some mutations [18], including the p.P533R homozy-
gous mutation present in sibships 1 and 2. In general, the
phenotypes between siblings within these sibships were
similar. While we cannot totally exclude phenotypic differ-
ences as playing a role in the different clinical outcomes
between siblings, in general we believe that there is a ten-
dency for family group clusters for disease presentation in
affected siblings, and that phenotypic differences are more
pronounced between, rather than within, families.
Compliance with ERT is important in order to achieve
maximal clinical effect [19]. In our case series, both
siblings in sibship 4 had a reported ERT compliance rate
of 60 %, and the younger sibling experienced progressive
joint contractures and cognitive delays similar to the
older sibling despite initiating therapy at an earlier age
While cognitive function is not believed to be directly
affected by ERT in patients with MPS I since laronidase
does not cross the blood brain barrier, improvements in
somatic disease following ERT may impact results of
cognitive testing. Likewise, interventions including hear-
ing aids, speech t
herapy and physical therapy, as well as psychosocial as-
sistance can optimize patient’s capacities and quality of
life. Improvements in treatment outcomes were aug-
mented in patients, such as those in sibship 7, who re-
ceived supportive care along with ERT. The available
data support the role of early or pre-symptomatic ERT
initiation in slowing disease progression in patients with
attenuated MPS I. Especially for disease manifestations
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that may be irreversible despite laronidase therapy, such
as cardiac and musculoskeletal symptoms, early treat-
ment is believed to be key in slowing the progression of
these symptoms [7].
Conclusion
These findings support early initiation of ERT with
laronidase prior to the onset of symptoms in patients
with attenuated MPS I in order to delay disease pro-
gression and/or prevent the development of severe
clinical manifestations.
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